Table 2 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
Treatment-emergent adverse events by Common Terminology Criteria for Adverse Events v5.0, grade 1–4 occurring in at least 10% of patients and all grade 5, at the patient level.
